SCHEMBL4287046

SCHEMBL4287046

Cc1ccc(C)c(C2=CC(N)(c3ccc(Cl)cc3)N=C(N)N2)c1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 3/20 0.33
MAPT P10636 3/20 0.33
GAA P10253 2/20 0.33
HPGD P15428 2/20 0.33
HSD17B10 Q99714 2/20 0.33
RECQL P46063 1/20 0.33
AGPAT2 O15120 1/20 0.32
CYP3A4 P08684 1/20 0.32
BACE1 P56817 3/20 0.32
APP P05067 1/20 0.32
IDO1 P14902 1/20 0.31
SLC6A3 Q01959 1/20 0.31
ALOX5 P09917 1/20 0.31
PTGS1 P23219 1/20 0.31
PTGS2 P35354 1/20 0.31
JAK2 O60674 1/20 0.30
LMNA P02545 1/20 0.30
CASP3 P42574 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4291033 0.85 AGPAT2 (0.43) AGPAT2CYP3A4IDO1JAK2
SCHEMBL4280058 0.80 HTR2B (0.39) ALDH1A1MAPTAGPAT2BACE1IDO1
SCHEMBL4280081 0.75 CYP1A2 (0.37) KDM4EMAPTGAABACE1LMNA
SCHEMBL4285195 0.73 HTR2B (0.35) ALDH1A1AGPAT2BACE1IDO1
SCHEMBL4282568 0.73 ALDH1A1 (0.41) ALDH1A1KDM4EHPGDHSD17B10RECQL
SCHEMBL4282261 0.72 HSD11B1 (0.39) BACE1LMNA
SCHEMBL4287050 0.72 AGPAT2 (0.33) ALDH1A1KDM4EMAPTGAAHPGD
SCHEMBL4282686 0.72 CYP1A2 (0.39) GAAHPGDCYP3A4SLC6A3LMNA
SCHEMBL4281458 0.68 TMPRSS4 (0.34) ALDH1A1IDO1SLC6A3
SCHEMBL5280419 0.63 AHR (0.42) ALDH1A1MAPTHPGDHSD17B10CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7419984-B2 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. (US) 2008-09-02 US claimed
US-20090099183-A1 PYRIMIDINES AND USES THEREOF CELL THERAPEUTICS, INC. (US) 2009-04-16 US disclosed
US-7419984-B2 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. (US) 2008-09-02 US disclosed
US-20040204386-A1 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204386-A1 Pyrimidines and uses thereof LPCAT3, LPCAT1, APRT ALDH1A1 1326/4885KDM4E 1842/4885MAPT 3800/4885
US-20090099183-A1 PYRIMIDINES AND USES THEREOF LPCAT3, LPCAT1, APRT ALDH1A1 1116/4885KDM4E 2160/4885MAPT 3707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.